Health Condition 1: G400- Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset Health Condition 2: G402- Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures Health Condition 3: G401- Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
Conditions
Interventions
Intervention1: Levetiracetam: Levetiracetam 500 mg twice daily and titrated upto 3000 mg per day depending upon seizure control.
Duration of the treatment will depend upon the clinical outcome as per
this carbamyl moiety provides potent anti-seizure activity.
Carbamazepine is also a mood stabilizer and is used to treat bipolar disorder. Carbamazepine is a prototypical sodium channel-blocking anti-
Sponsors
Institutional sponsored
Eligibility
Inclusion criteria
Inclusion criteria: The study will include all the newly diagnosed consenting adult patients of focal seizures without any other co-morbidities
Exclusion criteria
Exclusion criteria: Patients not willing to give written informed consent. Pregnant females. Patients already on treatment with study drugs. Patients of seizures others than focal seizures. Patients of head trauma within past one month. Patients with known contraindication or refractoriness to study drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Minimal adverse drug reactions and seizure freedomTimepoint: At 1 month, 3 months and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| PharmacoeconomicsTimepoint: At 6 months;Quality of life outcomeTimepoint: Before initiating treatment and at 6 months | — |
Countries
India
Contacts
Public ContactDr Nitin Patiyal
Dr. R.P.G.M.C, Kangra at Tanda
Outcome results
None listed